The primary objectives have not been met due to no patient enrollment therefore, the PI is requesting to close the study at this time.

The purpose of this study is to attempt to obtain an on-treatment biopsy in participants with non-small cell lung cancer who are receiving standard treatment with a drug that targets the PD-1 or PD-L1 protein.

Inclusion Criteria:

• Pathologically confirmed newly diagnosed or recurrent advanced Non Small Cell Lung Cancer/NSCLC that is PI-L1 high by immunohistochemistry (PD-L1 >/= 50%)
• Intended treatment with a PD-(L)1 inhibitor
• Age >/= 18 years
• Karnofsky Performance Status >/= 70% and medically fit to undergo a biopsy procedure

Exclusion Criteria:

• Any medical condition or any sites of disease that would preclude a biopsy
• Pregnant or breastfeeding women
• Cognitively impairment affecting ability to understand and provide informed consent
• Prior PD-(L)1 blockade treatment
• Chemotherapy within 6 months prior to enrollment

Participants with newly diagnosed or recurrent, PD-L1 high (>50%) metastatic non-small cell lung cancer without prior PD-(L)1 therapy

• Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.